K-STREET TRACKER
FOLLOW THE MONEY INTO THE SWAMP
Every federal lobbying filing tagged with a public-company ticker — who is spending, which firms they hire, and which members trade right around the filing.
Filings tracked
19,882
thru 2026-05-08
Total reported $
$2.7B
disclosed lobbying
Distinct clients
2,220
paying companies
Tickers targeted
1,207
public companies
💸 Top Spending Clients
| # | Client | Filings | Total $ |
|---|---|---|---|
| 1 |  PFIZER INC.PFE | 47 | $46.8M |
| 2 |  GENERAL MOTORS COMPANYGM | 61 | $46.8M |
| 3 |  META PLATFORMS INC. AND VARIOUS SUBSIDIARIESMETA | 12 | $44.9M |
| 4 | VISA INC.V | 45 | $37.7M |
| 5 |  AMAZON.COM SERVICES LLCAMZN | 36 | $32.8M |
| 6 |  LOCKHEED MARTIN CORPORATIONLMT | 73 | $29.0M |
| 7 |  FEDEX CORPORATIONFDX | 69 | $27.8M |
| 8 |  ELI LILLY AND COMPANYLLY | 56 | $27.1M |
| 9 |  ALTRIA CLIENT SERVICES LLCMO | 142 | $25.2M |
| 10 |  AMGEN INCAMGN | 19 | $24.9M |
| 11 |  COMCAST CORPORATIONCMCSV | 179 | $24.7M |
| 12 |  MERCK & CO INCMRK | 14 | $24.0M |
| 13 |  SOUTHERN COMPANYSO | 53 | $23.9M |
| 14 |  GOOGLE CLIENT SERVICES LLCGOOGL | 79 | $22.6M |
| 15 |  APPLE INCAAPL | 9 | $22.1M |
| 16 |  T-MOBILE USA INC.TMUS | 121 | $21.0M |
| 17 |  UNITEDHEALTH GROUP INCUNH | 19 | $20.4M |
| 18 |  VERIZON COMMUNICATIONS INC AND VARIOUS SUBSIDIARIESVZ | 40 | $20.1M |
| 19 |  OCCIDENTAL PETROLEUM CORPORATIONOXY | 30 | $19.7M |
| 20 |  MICROSOFT CORPORATIONMSFT | 103 | $18.8M |
| 21 |  QUALCOMM INCORPORATEDQCOM | 40 | $17.2M |
| 22 |  GENERAL DYNAMICS CORPGD | 11 | $17.0M |
| 23 |  BOEING COMPANYBA | 23 | $16.9M |
| 24 | THE CIGNA GROUP AND SUBSIDIARIES (FORMERLY CIGNA CORPORATION AND SUBSIDIARIES)CI | 13 | $16.9M |
| 25 |  ORACLE CORPORATIONORCL | 58 | $16.7M |
🎯 Top Lobbied Tickers
| # | Ticker | Filings | Total $ |
|---|---|---|---|
| 1 | META Meta Platforms Inc. | 129 | $50.2M |
| 2 | PFE Pfizer Inc. | 87 | $48.6M |
| 3 | GM General Motors Company | 103 | $48.4M |
| 4 | V Visa Inc. | 46 | $37.7M |
| 5 | AMZN Amazon.com Inc. | 80 | $35.3M |
| 6 | LMT Lockheed Martin Corporation | 88 | $29.4M |
| 7 | FDX FedEx Corporation | 82 | $28.3M |
| 8 | LLY Eli Lilly and Company | 83 | $28.1M |
| 9 | AMGN Amgen Inc. | 95 | $28.0M |
| 10 | MRK Merck & Co. Inc. | 92 | $27.5M |
| 11 | AAPL Apple Inc. | 64 | $26.8M |
| 12 | GOOGL Alphabet Inc. Class A | 123 | $26.6M |
| 13 | MO | 164 | $26.2M |
| 14 | SO Southern Company | 108 | $26.1M |
| 15 | UNH UnitedHealth Group Inc. | 67 | $23.9M |
| 16 | VZ Verizon Communications Inc. | 116 | $23.8M |
| 17 | TMUS | 159 | $22.7M |
| 18 |  CHTR | 137 | $22.6M |
| 19 | GD General Dynamics Corporation | 127 | $22.5M |
| 20 |  TAT&T Inc. | 134 | $21.6M |
| 21 | ORCL Oracle Corporation | 132 | $20.6M |
| 22 | CMCSA Comcast Corporation | 141 | $20.4M |
| 23 | CI The Cigna Group | 64 | $19.9M |
| 24 | OXY Occidental Petroleum Corporation | 36 | $19.9M |
| 25 | MSFT Microsoft Corporation | 122 | $19.2M |
🆕 Filtered Filings · JNJ
clear filters| Date | Ticker | Client | Registrant | Amount | Issue |
|---|---|---|---|---|---|
| 2026-04-20 | JNJ | JOHNSON & JOHNSON SERVICES INC | JOHNSON & JOHNSON SERVICES, INC. | $3.5M | - H.R. 1539, Medical Device Electronic Labeling Act, regarding all provisions - H.R. 929/S. 266, the Dr. Lorna Breen Health Care Provider Protection Reauthorization Act, regarding all provisions - H.R. 946 ORPHAN Cures Act, regarding all provisions - S.864, HELP Copays Act, regarding all provisions - H.R. 2214, Delinking Revenue from Unfair Gouging (DRUG) Act, regarding all provisions - H.R. 1492/S. 832, Ensuring Pathways to Innovative Cures (EPIC) Act - S. 1954/ H.R. 5526 Biosimilar Red Tape Elimination Act, regarding all provisions - H.R.2527, Early Detection of Vision Impairments for Children Act of 2025, regarding all provisions - PL117-169 The Inflation Reduction Act, regarding all provisions related to drug pricing and implementation - H.R.5343/S. 1717, the Ensuring Patient Access to Critical Breakthrough Products Act of 2025, regarding all provisions - H.R.4282, Contact Lens Prescription Verification Modernization Act, regarding all provisions - H.R. 4299, Protecting Patient Acc |
| 2026-04-20 | JNJ | JOHNSON & JOHNSON SERVICES INC. | TODD STRATEGY GROUP | $100K | Pharmacy Benefit Managers. 340B. Tort Litigation reform. Health care supply chain. S.864: HELP Copays Act. Inflation Reduction Act Implementation. |
| 2026-04-20 | JNJ | JOHNSON & JOHNSON SERVICES INC. | THE NICKLES GROUP, LLC | $80K | Issues related to mental health. Monitored Pandemic and All-Hazards Preparedness and Response Act (PAHPA) reauthorization. Issues related to pharmacy benefit management, including alternative funding programs. Monitored issues related to healthcare workforce shortages. Issues related to drug pricing. Issues related to ingredient safety. Implementation of P.L. 117-169, the Inflation Reduction Act, as it relates to drug pricing. Issues related to pharmacy benefit management. Monitored issues related to Medicare physician payment. Issues related to Most Favored Nation drug pricing. Monitor implementation of H.R. 1 (P.L. 119-21), One Big Beautiful Bill Act, as it relates to corporate and international taxes. Issues related to litigation reform. Issues related to tariffs. |
| 2026-04-20 | JNJ | JOHNSON & JOHNSON SERVICES INC. | FULCRUM PUBLIC AFFAIRS LLC | $60K | Issues related to public health, science and technology, sustainability, innovation, and competition. Issues related to public health, science and technology, sustainability, innovation, and competition. |
| 2026-04-20 | JNJ | JOHNSON & JOHNSON SERVICES INC | NAVIGATORS GLOBAL LLC (FORMERLY DC NAVIGATORS, LLC) | $60K | General issues regarding health care and public health issues. Issues related to drug pricing, including the 340b program. Issues related to maternal health, patient access and treatment, health care science and technology. Issues related to One Big Beautiful Bill Act (H.R.1) implementation. Issues related to the FY26 and FY27 budget and appropriations process. H.R.2675 - Protecting Our Courts from Foreign Manipulation Act of 2025 H.R.1109 - Litigation Transparency Act of 2025 General issues related to third party litigation. |
| 2026-04-20 | JNJ | JOHNSON & JOHNSON SERVICES INC | FARRAGUT PARTNERS LLP | $50K | Issues related to the 340B drug discount program. Medicare Part B. Biosimilar Legislation. Drug pricing legislation. Issues related to ASP reporting. Issues related to patient safety in attorney advertising. Vaccine coverage issues. Maternal health legislation. Issues related to the 340B drug discount program. Medicare Part B. Biosimilar Legislation. Drug pricing legislation. Issues related to ASP reporting. Issues related to patient safety in attorney advertising. Vaccine coverage issues. Maternal health legislation. |
| 2026-04-20 | JNJ | JOHNSON & JOHNSON SERVICES INC. | ML STRATEGIES, LLC | $50K | Issues related to cardiovascular health; H.R.5343 / S. 1717, the Ensuring Patient Access to Critical Breakthrough Products Act of 2025; issues related to Heart Recovery Awareness Day and H. Res. 1301, designating February 20th Heart Recovery Awareness Day |
| 2026-04-20 | JNJ | JOHNSON & JOHNSON SERVICES INC. | SPLITOAK STRATEGIES LLC | $50K | Value of prescription drugs and patient access Issues related to Medicare Parts B & D, MFN Promoting U.S. competitiveness while ensuring U.S. leadership role in developing medicines |
| 2026-04-20 | JNJ | JOHNSON & JOHNSON SERVICES INC. | BECKER & POLIAKOFF, P.A. | $30K | Educating members and staff on the company's presence in their districts and states and contributions to the wellbeing and health of their constituents. |
| 2026-04-20 | JNJ | JOHNSON & JOHNSON SERVICES INC. | THE COMPLETE AGENCY | $30K | Issues such as infant & maternal mortality, global pandemics, climate change & sustainability. |
| 2026-04-20 | JNJ | JOHNSON & JOHNSON SERVICES INC | HART HEALTH STRATEGIES | $0 | |
| 2026-04-19 | JNJ | JOHNSON & JOHNSON SERVICES INC. | BROWNSTEIN HYATT FARBER SCHRECK, LLP | $80K | Issues related to patient access Issues related to patents Legislation related to competition and intellectual property issues Drug pricing Issues related to corporate and international tax Research and development costs P.L. 119-21 (H.R. 1): One Big Beautiful Bill implementation Issues related to civil justice reform, including third party litigation funding reform Trade and tariffs affecting the pharmaceutical industry |
| 2026-04-17 | JNJ | JOHNSON & JOHNSON SERVICES INC | THE WASHINGTON TAX & PUBLIC POLICY GROUP | $50K | Issues related to corporate and international taxation. Issues related to OECD Pillar 1 and Pillar 2 negotiations and agreements on the taxation of global income and the potential impacts on financial reporting and the tax base of the U.S. and its Territories. Issues related to taxation of intellectual property income. Issues related to IRC sections 11, 59A, 951A, 250, 163(j), and 174. |
| 2026-04-16 | JNJ | JOHNSON & JOHNSON SERVICES INC | COVINGTON & BURLING LLP | $0 | |
| 2026-04-15 | JNJ | JOHNSON & JOHNSON SERVICES INC | CORNERSTONE GOVERNMENT AFFAIRS, INC. | $60K | Issues related to appropriations, animal welfare, and health policy. Issues related to appropriations, animal welfare, and health policy. |
| 2026-04-15 | JNJ | JOHNSON & JOHNSON | BRICK STREET STRATEGY | $30K | Medical supply chain reforms HR 6549, VA Contracting and Procurement Act PBM |
| 2026-04-14 | JNJ | BROWNSTEIN HYATT FARBER SCHRECK LLP OBO JOHNSON & JOHNSON | RICHARD BURNESS | $0 | |
| 2026-03-04 | JNJ | JOHNSON & JOHNSON SERVICES INC. | FULCRUM PUBLIC AFFAIRS LLC | $60K | Issues related to public health, science and technology, sustainability, innovation, and competition. Issues related to public health, science and technology, sustainability, innovation, and competition. |
| 2026-01-20 | JNJ | JOHNSON & JOHNSON SERVICES INC | JOHNSON & JOHNSON SERVICES, INC. | $1.5M | - H.R. 1539, Medical Device Electronic Labeling Act, regarding all provisions - H.R. 929/S. 266, the Dr. Lorna Breen Health Care Provider Protection Reauthorization Act, regarding all provisions - H.R. 946 ORPHAN Cures Act, regarding all provisions - S.864, HELP Copays Act, regarding all provisions - H.R. 2214, Delinking Revenue from Unfair Gouging (DRUG) Act, regarding all provisions - H.R. 1492/S. 832, Ensuring Pathways to Innovative Cures (EPIC) Act - S. 1954/ H.R. 5526 Biosimilar Red Tape Elimination Act, regarding all provisions - H.R.2527, Early Detection of Vision Impairments for Children Act of 2025, regarding all provisions - PL117-169 The Inflation Reduction Act, regarding all provisions related to drug pricing and implementation - H.R.5343/S. 1717, the Ensuring Patient Access to Critical Breakthrough Products Act of 2025, regarding all provisions - H.R.4282, Contact Lens Prescription Verification Modernization Act, regarding all provisions - H.R. 4299, Protecting Patient Acc |
| 2026-01-20 | JNJ | JOHNSON & JOHNSON SERVICES INC. | THE NICKLES GROUP, LLC | $70K | Issues related to mental health. Issues related to SUPPORT Act Reauthorization. Monitored Pandemic and All-Hazards Preparedness and Response Act (PAHPA) reauthorization. Issues related to pharmacy benefit management, including alternative funding programs. Monitored issues related to healthcare workforce shortages. Issues related to drug pricing. Issues related to ingredient safety. Implementation of P.L. 117-169, the Inflation Reduction Act, as it relates to drug pricing. Monitored issues related to Ambulatory Surgical Centers. Issues related to pharmacy benefit management. Monitored issues related to Medicare physician payment. Issues related to Most Favored Nation drug pricing. Monitor implementation of H.R. 1 (P.L. 119-21), One Big Beautiful Bill Act, as it relates to corporate and international taxes. Issues related to litigation reform. Issues related to tariffs. |
| 2026-01-20 | JNJ | JOHNSON & JOHNSON SERVICES INC. | FULCRUM PUBLIC AFFAIRS LLC | $60K | Issues related to public health, science and technology, sustainability, innovation, and competition. Issues related to public health, science and technology, sustainability, innovation, and competition. |
| 2026-01-20 | JNJ | JOHNSON & JOHNSON SERVICES INC | NAVIGATORS GLOBAL LLC (FORMERLY DC NAVIGATORS, LLC) | $60K | General issues regarding health care and public health issues. Issues related to drug pricing, including the 340b program. Issues related to maternal health, patient access and treatment, health care science and technology. Issues related to One Big Beautiful Bill Act (H.R.1) implementation. Issues related to the FY26 budget and appropriations process. H.R.2675 - Protecting Our Courts from Foreign Manipulation Act of 2025 H.R.1109 - Litigation Transparency Act of 2025 General issues related to third party litigation. |
| 2026-01-20 | JNJ | JOHNSON & JOHNSON SERVICES INC. | TODD STRATEGY GROUP | $60K | Pharmacy Benefit Managers. 340B. Tort Litigation reform. Health care supply chain. S.864 - HELP Copays Act. Inflation Reduction Act Implementation. |
| 2026-01-20 | JNJ | JOHNSON & JOHNSON SERVICES INC. | ML STRATEGIES, LLC | $50K | Issues related to cardiovascular health; H.R.5343 / S. 1717, the Ensuring Patient Access to Critical Breakthrough Products Act of 2025; issues related to Heart Recovery Awareness Day and H. Res. 1301, designating February 20th Heart Recovery Awareness Day |
| 2026-01-20 | JNJ | JOHNSON & JOHNSON SERVICES INC | FARRAGUT PARTNERS LLP | $50K | Issues related to the 340B drug discount program. Medicare Part B. Biosimilar Legislation. Drug pricing legislation. Issues related to ASP reporting. Issues related to patient safety in attorney advertising. Vaccine coverage issues. Maternal health legislation. Issues related to the 340B drug discount program. Medicare Part B. Biosimilar Legislation. Drug pricing legislation. Issues related to ASP reporting. Issues related to patient safety in attorney advertising. Vaccine coverage issues. Maternal health legislation. |
| 2026-01-20 | JNJ | JOHNSON & JOHNSON SERVICES INC. | SPLITOAK STRATEGIES LLC | $50K | Value of prescription drugs and patient access Issues related to Medicare Parts B & D P.L. 119-21 H.R. 946/S. 1862, ORPHAN Cures Act H.R. 2483, SUPPORT for Patients and Communities Reauthorization Act of 2025/Public Law No: 119-44 Promoting U.S. competitiveness while ensuring U.S. leadership role in developing medicines |
| 2026-01-20 | JNJ | JOHNSON & JOHNSON SERVICES INC | THE WASHINGTON TAX & PUBLIC POLICY GROUP | $40K | Issues related to corporate and international taxation. Issues related to OECD Pillar 1 and Pillar 2 negotiations and agreements on the taxation of global income and the potential impacts on financial reporting and the tax base of the U.S. and its Territories. Issues related to taxation of intellectual property income. Issues related to IRC sections 11, 164(a), 59A, 951A, 250, 163(j), 174 (H.R. 1990, S. 1639, H.R. 574, S. 187, H.R. 1062, H.R. 1347, S. 559, S. 1688, H.R. 1 - Sections 70321, 70322, 70323, 70331, 70303, 70302). |
| 2026-01-20 | JNJ | JOHNSON & JOHNSON SERVICES INC. | THE COMPLETE AGENCY | $30K | Issues such as infant & maternal mortality, global pandemics, climate change & sustainability. |
| 2026-01-19 | JNJ | JOHNSON & JOHNSON SERVICES INC. | BROWNSTEIN HYATT FARBER SCHRECK, LLP | $80K | Issues related to patient access Issues related to patents Legislation related to competition and intellectual property issues Drug pricing Issues related to corporate and international tax Research and development costs P.L. 119-21 (H.R. 1): One Big Beautiful Bill implementation Issues related to civil justice reform, including third party litigation funding reform Trade and tariffs affecting the pharmaceutical industry |
| 2026-01-17 | JNJ | JOHNSON & JOHNSON SERVICES INC. | BECKER & POLIAKOFF, P.A. | $30K | Educating members and staff on the company's presence in their districts and states and contributions to the wellbeing and health of their constituents. |
| 2026-01-16 | JNJ | JOHNSON & JOHNSON SERVICES INC | HART HEALTH STRATEGIES | $0 | |
| 2026-01-09 | JNJ | BROWNSTEIN HYATT FARBER SCHRECK LLP OBO JOHNSON & JOHNSON | RICHARD BURNESS | $0 | |
| 2026-01-08 | JNJ | JOHNSON & JOHNSON SERVICES INC | COVINGTON & BURLING LLP | $0 | |
| 2026-01-07 | JNJ | JOHNSON & JOHNSON SERVICES INC | CORNERSTONE GOVERNMENT AFFAIRS, INC. | $60K | Issues related to appropriations, animal welfare, and health policy. Issues related to appropriations, animal welfare, and health policy. |
| 2026-01-05 | JNJ | JOHNSON & JOHNSON | BRICK STREET STRATEGY | $30K | Medical supply chain reforms HR 6549, VA Contracting and Procurement Act |
| 2025-10-20 | JNJ | JOHNSON & JOHNSON SERVICES INC | JOHNSON & JOHNSON SERVICES, INC. | $2.5M | Issues related to - OECD proposals on global tax & implementation and/or related Presidential executive orders - corporate tax provisions in OBBB Issues related to: - Veterans Administration and Veterans Health Administration procurement and contracting processes for medical technology - VA Program - Issues related to USMCA review and renegotiation - H.R. 1539, Medical Device Electronic Labeling Act, regarding all provisions - H.R. 929/S. 266, the Dr. Lorna Breen Health Care Provider Protection Reauthorization Act, regarding all provisions - H.R. 946 ORPHAN Cures Act, regarding all provisions - S.864, HELP Copays Act, regarding all provisions - H.R. 2214, Delinking Revenue from Unfair Gouging (DRUG) Act, regarding all provisions - H.R. 1492/S. 832, Ensuring Pathways to Innovative Cures (EPIC) Act - S. 1954/ H.R. 5526 Biosimilar Red Tape Elimination Act, regarding all provisions - H.R.2527, Early Detection of Vision Impairments for Children Act of 2025, regarding all provisions - |
| 2025-10-20 | JNJ | JOHNSON & JOHNSON SERVICES INC. | FULCRUM PUBLIC AFFAIRS LLC | $60K | Issues related to public health, science and technology, sustainability, innovation, and competition. Issues related to public health, science and technology, sustainability, innovation, and competition. |
| 2025-10-20 | JNJ | JOHNSON & JOHNSON SERVICES INC | NAVIGATORS GLOBAL LLC (FORMERLY DC NAVIGATORS, LLC) | $60K | General issues regarding health care and public health issues. Issues related to drug pricing, including the 340b program. Issues related to maternal health, patient access and treatment, health care science and technology. Issues related to One Big Beautiful Bill Act (H.R.1) implementation. Issues related to the FY26 budget and appropriations process. H.R.2675 - Protecting Our Courts from Foreign Manipulation Act of 2025 H.R.1109 - Litigation Transparency Act of 2025 |
| 2025-10-20 | JNJ | JOHNSON & JOHNSON SERVICES INC. | THE NICKLES GROUP, LLC | $50K | H.R. 1 (P.L. 119-21), One Big Beautiful Bill Act and pharmacy benefit management. Issues related to mental health. Issues related to SUPPORT Act Reauthorization. Monitored Pandemic and All-Hazards Preparedness and Response Act (PAHPA) reauthorization. Issues related to pharmacy benefit management, including alternative funding programs. Monitored issues related to healthcare workforce shortages. Issues related to drug pricing. Issues related to ingredient safety. Implementation of P.L. 117-169, the Inflation Reduction Act, as it relates to drug pricing. Monitored issues related to Ambulatory Surgical Centers. Issues related to pharmacy benefit management. Monitored issues related to Medicare physician payment. H.R. 1 (P.L. 119-21), One Big Beautiful Bill Act and issues related to drug pricing. Issues related to Most Favored Nation drug pricing. H.R. 946 / S. 1862, ORPHAN Cures Act. H.R. 1 (P.L. 119-21), One Big Beautiful Bill Act, as it relates to corporate and international taxes. |
| 2025-10-20 | JNJ | JOHNSON & JOHNSON SERVICES INC | FARRAGUT PARTNERS LLP | $50K | Issues related to the 340B drug discount program. Medicare Part B. Biosimilar Legislation. Drug pricing legislation. Issues related to ASP reporting. Issues related to patient safety in attorney advertising. Vaccine coverage issues. Maternal health legislation. Issues related to the 340B drug discount program. Medicare Part B. Biosimilar Legislation. Drug pricing legislation. Issues related to ASP reporting. Issues related to patient safety in attorney advertising. Vaccine coverage issues. Maternal health legislation. |
| 2025-10-20 | JNJ | JOHNSON & JOHNSON SERVICES INC. (FORMERLY ABIOMED INC.) | ML STRATEGIES, LLC | $50K | Issues relating to education on heart recovery as the standard of care, cardiovascular health, and diversity in cardiovascular clinical trials; issues relating medical device supply chains; issues related to Medicare coverage reform; issues related to health equity |
| 2025-10-20 | JNJ | JOHNSON & JOHNSON SERVICES INC. | SPLITOAK STRATEGIES LLC | $50K | Value of prescription drugs and patient access Issues related to Medicare Parts B & D P.L. 119-21 H.R. 946/S. 1862, ORPHAN Cures Act H.R. 2483, SUPPORT Act Issues related to - H.R. 1109, the Litigation Transparency Act of 2025, and transparency in domestic third-party litigation funding - the Protecting Our Courts from Foreign Manipulation Act, and transparency in foreign third-party litigation funding |
| 2025-10-20 | JNJ | JOHNSON & JOHNSON SERVICES INC | COVINGTON & BURLING LLP | $10K | Bankruptcy Law. |
| 2025-10-20 | JNJ | JOHNSON & JOHNSON SERVICES INC | HART HEALTH STRATEGIES | $0 | |
| 2025-10-17 | JNJ | JOHNSON & JOHNSON SERVICES INC. | BROWNSTEIN HYATT FARBER SCHRECK, LLP | $80K | Issues related to patient access Issues related to patents Legislation related to competition and intellectual property issues Drug pricing Issues related to corporate and international tax Research and development costs H.R.1 Implementation Issues related to civil justice reform, including third party litigation funding reform Trade and tariffs affecting the pharmaceutical industry |
| 2025-10-17 | JNJ | JOHNSON & JOHNSON SERVICES INC. | THE COMPLETE AGENCY | $30K | Issues such as infant & maternal mortality, global pandemics, climate change & sustainability. |
| 2025-10-17 | JNJ | JOHNSON & JOHNSON SERVICES INC. | BECKER & POLIAKOFF, P.A. | $30K | Educating members and staff on the company's presence in their districts and states and contributions to the wellbeing and health of their constituents. |
| 2025-10-16 | JNJ | JOHNSON & JOHNSON SERVICES INC | THE WASHINGTON TAX & PUBLIC POLICY GROUP | $50K | Issues related to corporate and international taxation. Issues related to OECD Pillar 1 and Pillar 2 negotiations and agreements on the taxation of global income and the potential impacts on financial reporting and the tax base of the U.S. and its Territories. Issues related to taxation of intellectual property income. Issues related to IRC sections 11, 164(a), 59A, 951A, 250, 163(j), 174 (H.R. 1990, S. 1639, H.R. 574, S. 187, H.R. 1062, H.R. 1347, S. 559, S. 1688, H.R. 1 - Sections 70321, 70322, 70323, 70331, 70303, 70302) Issues related third party ligation financing (S. 1821, H.R. 1 - Section 70605). |
| 2025-10-12 | JNJ | JOHNSON & JOHNSON SERVICES INC. | TODD STRATEGY GROUP | $60K | Pharmacy Benefit Managers. 340B. Tort Litigation reform. Health care supply chain. S.864 - HELP Copays Act. Inflation Reduction Act Implementation. |
| 2025-10-11 | JNJ | JOHNSON & JOHNSON SERVICES INC. | SPLITOAK STRATEGIES LLC | $50K | Value of prescription drugs Issues related to Medicare Parts B & D Implementation of P.L. 117-169, Inflation Reduction Act of 2022 |
| 2025-10-10 | JNJ | BROWNSTEIN HYATT FARBER SCHRECK LLP OBO JOHNSON & JOHNSON | MR. RICHARD BURNESS | $0 | |
| 2025-10-06 | JNJ | JOHNSON & JOHNSON SERVICES INC | CORNERSTONE GOVERNMENT AFFAIRS, INC. | $60K | Issues related to appropriations, animal welfare, and health policy. Issues related to appropriations, animal welfare, and health policy. |
| 2025-10-02 | JNJ | JOHNSON & JOHNSON | BRICK STREET STRATEGY | $30K | Medical supply chain reforms |
| 2025-08-05 | JNJ | JOHNSON & JOHNSON | BRICK STREET STRATEGY | $30K | Medical supply chain reforms |
| 2025-07-21 | JNJ | JOHNSON & JOHNSON SERVICES INC | JOHNSON & JOHNSON SERVICES, INC. | $1.0M | - H.R. 1539, Medical Device Electronic Labeling Act, regarding all provisions - S. 266, the Dr. Lorna Breen Health Care Provider Protection Reauthorization Act, regarding all provisions - H.R. 946 ORPHAN Cures Act, regarding all provisions - S.864, HELP Copays Act, regarding all provisions - H.R. 2214, Delinking Revenue from Unfair Gouging (DRUG) Act, regarding all provisions - H.R. 1492/S. 832, Ensuring Pathways to Innovative Cures (EPIC) Act - S. 1954, Biosimilar Red Tape Elimination Act, regarding all provisions - H.R.2527, Early Detection of Vision Impairments for Children Act of 2025, regarding all provisions - PL117-169 The Inflation Reduction Act, regarding all provisions related to drug pricing and implementation Issues related to - direct to consumer advertising - clinical trial modernization - biosimilars - cardiovascular health - 340B - Heart Recovery Awareness Day & H.Res. 1301, designating February 20th Heart Recovery Awareness Day - obesity treatments - Issues related t |
| 2025-07-21 | JNJ | JOHNSON & JOHNSON SERVICES INC. | FULCRUM PUBLIC AFFAIRS LLC | $60K | Issues related to public health, science and technology, sustainability, innovation, and competition. Issues related to public health, science and technology, sustainability, innovation, and competition. |
| 2025-07-21 | JNJ | JOHNSON & JOHNSON SERVICES INC | NAVIGATORS GLOBAL LLC (FORMERLY DC NAVIGATORS, LLC) | $60K | General issues regarding health care and public health issues. Issues related to drug pricing, including the 340b program. Issues related to maternal health, patient access and treatment, health care science and technology. H.R.1 - One Big Beautiful Bill Act. Issues related to the FY26 budget and appropriations process. |
| 2025-07-21 | JNJ | JOHNSON & JOHNSON SERVICES INC | FARRAGUT PARTNERS LLP | $50K | Issues related to the 340B drug discount program. Medicare Part B. Biosimilar Legislation. Drug pricing legislation. Issues related to ASP reporting. Issues related to patient safety in attorney advertising. Vaccine coverage issues. Maternal health legislation. Issues related to the 340B drug discount program. Medicare Part B. Biosimilar Legislation. Drug pricing legislation. Issues related to ASP reporting. Issues related to patient safety in attorney advertising. Vaccine coverage issues. Maternal health legislation. |
| 2025-07-21 | JNJ | JOHNSON & JOHNSON SERVICES INC. (FORMERLY ABIOMED INC.) | ML STRATEGIES, LLC | $50K | Issues relating to education on heart recovery as the standard of care, cardiovascular health, and diversity in cardiovascular clinical trials; issues relating medical device supply chains; issues related to Medicare coverage reform; issues related to health equity |
| 2025-07-21 | JNJ | JOHNSON & JOHNSON SERVICES INC. | SPLITOAK STRATEGIES LLC | $50K | Value of prescription drugs and patient access Issues related to Medicare Parts B & D P.L. 119-21 H.R. 946/S. 1862, ORPHAN Cures Act H.R. 2483, SUPPORT Act |
| 2025-07-21 | JNJ | JOHNSON & JOHNSON SERVICES INC. | BECKER & POLIAKOFF, P.A. | $30K | Educating members and staff on the company's presence in their districts and states and contributions to the wellbeing and health of their constituents. |
| 2025-07-21 | JNJ | JOHNSON & JOHNSON SERVICES INC | THE WASHINGTON TAX & PUBLIC POLICY GROUP | $30K | Issues related to corporate and international taxation. Issues related to OECD Pillar 1 and Pillar 2 negotiations and agreements on the taxation of global income and the potential impacts on the tax base of the U.S. and its Territories. Issues related to IRC sections 11, 164(a), 59A, 951A, 250, 163(j), 174 (H.R. 1990, S. 1639, H.R. 574, S. 187, H.R. 1062, H.R. 1347, S. 559, S. 1688, H.R. 1 - Sections 70321, 70322, 70323, 70331, 70303, 70302) Issues related third party ligation financing (S. 1821, H.R. 1 - Section 70605). |
| 2025-07-21 | JNJ | JOHNSON & JOHNSON SERVICES INC | COVINGTON & BURLING LLP | $20K | Bankruptcy Law. |
| 2025-07-19 | JNJ | JOHNSON & JOHNSON SERVICES INC. | TODD STRATEGY GROUP | $60K | Pharmacy Benefit Managers. 340B. Tort Litigation reform. Health care supply chain. S.864 - HELP Copays Act. Inflation Reduction Act Implementation. |
| 2025-07-18 | JNJ | JOHNSON & JOHNSON SERVICES INC. | BROWNSTEIN HYATT FARBER SCHRECK, LLP | $80K | Issues related to patient access Issues related to patents Legislation related to competition and intellectual property issues Drug pricing Issues related to corporate and international tax Research and development costs H.R.1 One Big Beautiful Bill Issues related to civil justice reform, including third party litigation funding reform Trade and tariffs affecting the pharmaceutical industry |
| 2025-07-18 | JNJ | JOHNSON & JOHNSON SERVICES INC | THE WASHINGTON TAX & PUBLIC POLICY GROUP | $30K | Issues related to corporate and international taxation. Issues related to OECD Pillar 1 and Pillar 2 negotiations and agreements on the taxation of global income and the potential impacts on the tax base of the U.S. and its Territories. Issues related to IRC sections 11, 164(a), 59A, 951A, 250, 163(j), 174 (H.R. 1990, S. 1639, H.R. 574, S. 187, H.R. 1062, H.R. 1347, S. 559, S. 1688, H.R. 1 - Sections 70321, 70322, 70323, 70331, 70303, 70302) Issues related third party ligation financing (S. 1821, H.R. 1 - Section 7060). |
| 2025-07-18 | JNJ | JOHNSON & JOHNSON SERVICES INC. | THE COMPLETE AGENCY | $30K | Issues such as infant & maternal mortality, global pandemics, climate change & sustainability. |
| 2025-07-18 | JNJ | JOHNSON & JOHNSON SERVICES INC | COVINGTON & BURLING LLP | $0 | Bankruptcy Law. |
| 2025-07-17 | JNJ | JOHNSON & JOHNSON SERVICES INC. | THE NICKLES GROUP, LLC | $50K | H.R. 1, One Big Beautiful Bill Act and pharmacy benefit management. Issues related to mental health. Issues related to SUPPORT Act Reauthorization. Monitored Pandemic and All-Hazards Preparedness and Response Act (PAHPA) reauthorization. Issues related to pharmacy benefit management, including alternative funding programs. Monitored issues related to healthcare workforce shortages. Issues related to drug pricing. Issues related to ingredient safety. Implementation of P.L. 117-169, the Inflation Reduction Act, as it relates to drug pricing. Monitored issues related to Ambulatory Surgical Centers. Issues related to pharmacy benefit management. Monitored issues related to Medicare physician payment. H.R. 1, One Big Beautiful Bill Act and issues related to drug pricing. Issues related to Most Favored Nation drug pricing. H.R. 946 / S. 1862, ORPHAN Cures Act. H.R. 1, One Big Beautiful Bill Act, as it relates to corporate and international taxes. Issues related to litigation reform. |
| 2025-07-10 | JNJ | JOHNSON & JOHNSON SERVICES INC | HART HEALTH STRATEGIES | $0 | |
| 2025-07-09 | JNJ | JOHNSON & JOHNSON SERVICES INC | CORNERSTONE GOVERNMENT AFFAIRS, INC. | $60K | Issues related to appropriations, animal welfare, and health policy. Issues related to appropriations, animal welfare, and health policy. |
| 2025-07-05 | JNJ | BROWNSTEIN HYATT FARBER SCHRECK LLP OBO JOHNSON & JOHNSON | MR. RICHARD BURNESS | $0 | |
| 2025-06-26 | JNJ | JOHNSON & JOHNSON SERVICES INC. | THE NICKLES GROUP, LLC | $50K | Issues related to mental health. Issues related to SUPPORT Act reauthorization. Monitored Pandemic and All-Hazards Preparedness and Response Act (PAHPA) reauthorization. Issues related to pharmacy benefit management, including alternative funding programs. Monitored issues related to healthcare workforce shortages. Monitored issues related to drug pricing. H.R. 1968 (P.L. 119-4), Full-Year Continuing Appropriations and Extensions Act, 2025. Monitored implementation of P.L. 117-169, the Inflation Reduction Act, as it relates to drug pricing. Monitored issues related to Ambulatory Surgical Centers. Issues related to pharmacy benefit management. Monitored issues related to Medicare physician payment. H.R. 1968 (P.L. 119-4), Full-Year Continuing Appropriations and Extensions Act, 2025. H.R. 1990, the American Innovation and R&D Competitiveness Act, and issues related to the R&D tax credit. Issues related to the extension of the 2017 Tax Cut and Jobs Act provisions, and corporate and in |
| 2025-04-30 | JNJ | JOHNSON & JOHNSON SERVICES INC. | BROWNSTEIN HYATT FARBER SCHRECK, LLP | $80K | Issues related to patient access Issues related to patents Legislation related to competition and intellectual property issues Drug pricing Issues related to corporate and international tax Research and development costs Issues related to civil justice reform, including third party litigation funding reform |
| 2025-04-21 | JNJ | JOHNSON & JOHNSON SERVICES INC | JOHNSON & JOHNSON SERVICES, INC. | $3.3M | - Issues related to the SUPPORT Act Issues related to - artificial intelligence - data privacy - cybersecurity - robotics Issues related to - OECD proposals on global tax & implementation and/or related Presidential executive orders - corporate tax provisions in TCJA including in 2025 reconciliation bills - Issues related to Veterans Administration and Veterans Health Administration procurement and contracting processes for medical technology - H.R. 1539, Medical Device Electronic Labeling Act, regarding all provisions - H.R. XXXX/ S. 266, the Dr. Lorna Breen Health Care Provider Protection Reauthorization Act, regarding all provisions - H.R. 946 ORPHAN Cures Act, regarding all provisions - S.864, H.R. XXX HELP Copays Act, regarding all provisions - H.R. 2214/ S. XXXX Delinking Revenue from Unfair Gouging (DRUG) Act, regarding all provisions - H.R. 1492/S. 832, Ensuring Pathways to Innovative Cures (EPIC) Act - PL117-169 The Inflation Reduction Act, regarding all provisions rel |
| 2025-04-21 | JNJ | JOHNSON & JOHNSON SERVICES INC. | TODD STRATEGY GROUP | $60K | Pharmacy Benefit Managers. 340B. Tort Litigation reform. Health care supply chain. S.864 - HELP Copays Act. Inflation Reduction Act Implementation. |
| 2025-04-21 | JNJ | JOHNSON & JOHNSON SERVICES INC. | FULCRUM PUBLIC AFFAIRS LLC | $60K | Issues related to public health, science and technology, sustainability, innovation, and competition. Issues related to public health, science and technology, sustainability, innovation, and competition. |
| 2025-04-21 | JNJ | JOHNSON & JOHNSON SERVICES INC | NAVIGATORS GLOBAL LLC (FORMERLY DC NAVIGATORS, LLC) | $60K | General issues regarding health care and public health issues. Issues related to drug pricing, including the 340b program. Issues related to maternal health, patient access and treatment, health care science and technology. Issues related to the FY25 budget and appropriations process; H.R.1968 - Full-Year Continuing Appropriations and Extensions Act, 2025. Issues related to the FY26 budget and appropriations process. |
| 2025-04-21 | JNJ | JOHNSON & JOHNSON SERVICES INC. (FORMERLY ABIOMED INC.) | ML STRATEGIES, LLC | $50K | Issues relating to education on heart recovery as the standard of care, cardiovascular health, and diversity in cardiovascular clinical trials; issues relating medical device supply chains; issues related to Medicare coverage reform; issues related to health equity |
| 2025-04-21 | JNJ | JOHNSON & JOHNSON SERVICES INC | FARRAGUT PARTNERS LLP | $50K | Issues related to the 340B drug discount program. Medicare Part B. Biosimilar Legislation. Drug pricing legislation. Issues related to ASP reporting. Issues related to patient safety in attorney advertising. Vaccine coverage issues. Maternal health legislation. Issues related to the 340B drug discount program. Medicare Part B. Biosimilar Legislation. Drug pricing legislation. Issues related to ASP reporting. Issues related to patient safety in attorney advertising. Vaccine coverage issues. Maternal health legislation. |
| 2025-04-21 | JNJ | JOHNSON & JOHNSON SERVICES INC. | SPLITOAK STRATEGIES LLC | $50K | H.R.2483, SUPPORT for Patients and Communities Reauthorization Act of 2025; H.R.1968 - Full-Year Continuing Appropriations and Extensions Act, 2025 |
| 2025-04-21 | JNJ | JOHNSON & JOHNSON SERVICES INC. | THE NICKLES GROUP, LLC | $40K | Issues related to mental health. Issues related to SUPPORT Act reauthorization. Monitored Pandemic and All-Hazards Preparedness and Response Act (PAHPA) reauthorization. Issues related to pharmacy benefit management, including alternative funding programs. Monitored issues related to healthcare workforce shortages. Monitored issues related to drug pricing. H.R. 1968 (P.L. 119-4), Full-Year Continuing Appropriations and Extensions Act, 2025. Monitored implementation of P.L. 117-169, the Inflation Reduction Act, as it relates to drug pricing. Monitored issues related to Ambulatory Surgical Centers. Issues related to pharmacy benefit management. Monitored issues related to Medicare physician payment. H.R. 1968 (P.L. 119-4), Full-Year Continuing Appropriations and Extensions Act, 2025. H.R. 1990, the American Innovation and R&D Competitiveness Act, and issues related to the R&D tax credit. Issues related to the extension of the 2017 Tax Cut and Jobs Act provisions, and corporate and in |
| 2025-04-21 | JNJ | JOHNSON & JOHNSON SERVICES INC | THE WASHINGTON TAX & PUBLIC POLICY GROUP | $30K | Issues related to corporate and international taxation. Issues related to OECD Pillar 1 and Pillar 2 negotiations and agreements on the taxation of global income and the potential impacts on the tax base of the U.S. and its Territories. Issues related to IRC sections 11, 164(a), 951A, 250, 163(j), 174 and 41 (H.R. 1990, H.R. 574, S. 187, H.R. 1062). Issues related to interest deductibility. (H.R. 1347, S. 559) |
| 2025-04-21 | JNJ | JOHNSON & JOHNSON SERVICES INC. | THE COMPLETE AGENCY | $30K | Issues such as infant & maternal mortality, global pandemics, climate change & sustainability. |
| 2025-04-20 | JNJ | JOHNSON & JOHNSON SERVICES INC. | BECKER & POLIAKOFF, P.A. | $30K | Issues related to corporate and international tax. Research and development costs. |
| 2025-04-18 | JNJ | JOHNSON & JOHNSON SERVICES INC. | BROWNSTEIN HYATT FARBER SCHRECK, LLP | $80K | Issues related to patient access Issues related to patents Legislation related to competition and intellectual property issues Drug pricing Issues related to corporate and international tax Research and development costs Issues related to civil justice reform, including third party litigation funding reform |
| 2025-04-18 | JNJ | JOHNSON & JOHNSON SERVICES INC | COVINGTON & BURLING LLP | $20K | Bankruptcy Law. |
| 2025-04-18 | JNJ | JOHNSON & JOHNSON SERVICES INC | HART HEALTH STRATEGIES | $20K | |
| 2025-04-11 | JNJ | JOHNSON & JOHNSON SERVICES INC | CORNERSTONE GOVERNMENT AFFAIRS, INC. | $60K | Issues related to appropriations, animal welfare, and health policy. Issues related to appropriations, animal welfare, and health policy. |
| 2025-04-09 | JNJ | JOHNSON & JOHNSON | BRICK STREET STRATEGY | $30K | Medical supply chain reforms |
| 2025-04-06 | JNJ | BROWNSTEIN HYATT FARBER SCHRECK LLP OBO JOHNSON & JOHNSON | MR. RICHARD BURNESS | $0 | |
| 2025-03-24 | JNJ | JOHNSON & JOHNSON SERVICES INC. | BECKER & POLIAKOFF, P.A. | $0 | pharmaceutical, biotechnology, and medical technologies issues |
| 2025-02-04 | JNJ | JOHNSON & JOHNSON SERVICES INC. | SPLITOAK STRATEGIES LLC | $50K | Value of prescription drugs Issues related to Medicare Parts B & D Implementation of P.L. 117-169, Inflation Reduction Act of 2022 H.R.4531/S.3393 - Support for Patients and Communities Reauthorization Act - pharmacy delivery to administering practitioners |
| 2025-02-04 | JNJ | BROWNSTEIN HYATT FARBER SCHRECK LLP OBO JOHNSON & JOHNSON | MR. RICHARD BURNESS | $0 | Corporate Alternative Minimum Tax Research and Development Expenses |
| 2025-01-21 | JNJ | JOHNSON & JOHNSON SERVICES INC | JOHNSON & JOHNSON SERVICES, INC. | $1.5M | Issues related to: - Contact lens safety, peripheral artery disease, and stroke care, specifically to provisions regarding appropriations report language - Appropriations for Labor Health and Human Services - NIH funding - S 1375/HR 830, "HELP Copays Act", regarding all provisions. - PL 117-169, "The Inflation Reduction Act", regarding provisions impacting drug pricing and implementation. - PL 113-5 "Pandemic All Hazards Preparedness Reauthorization", regarding all provisions. - S 1355/HR 2940, "PASTEUR Act", regarding all provisions. - HR 3723, "Medical Device Electronic Labeling Act", regarding all provisions. - HR 2748, "Contact Lens Prescription Verification Modernization Act", regarding all provisions. - HR 4261, "Amputation Reduction and Compassion Act", regarding all provisions. - S 3131/HR 5539, "ORPHAN Cures Act", regarding all provisions. - HR 5372, "Expanding Access to Seniors Access to Lower Cost Medicines Act of 2023", regarding all provisions. - S 2305, "The Biosimilar |
| 2025-01-21 | JNJ | JOHNSON & JOHNSON SERVICES INC. | FULCRUM PUBLIC AFFAIRS LLC | $60K | Issues related to public health, science and technology, sustainability, innovation, and diversity and inclusion issues, and competition. Issues related to public health, science and technology, sustainability, innovation, and diversity and inclusion issues, and competition. |
| 2025-01-21 | JNJ | JOHNSON & JOHNSON SERVICES INC. | TODD STRATEGY GROUP | $60K | Pharmacy Benefit Managers. 340B. Tort Litigation reform. Health care supply chain. S.1375/HR 830 - HELP Copays Act. Inflation Reduction Act Implementation. |
| 2025-01-21 | JNJ | JOHNSON & JOHNSON SERVICES INC | FARRAGUT PARTNERS LLP | $50K | Issues related to the 340B drug discount program. Medicare Part B. Biosimilar Legislation. Drug pricing legislation. Issues related to ASP reporting. Issues related to patient safety in attorney advertising. Vaccine coverage issues. Maternal health legislation. Issues related to the 340B drug discount program. Medicare Part B. Biosimilar Legislation. Drug pricing legislation. Issues related to ASP reporting. Issues related to patient safety in attorney advertising. Vaccine coverage issues. Maternal health legislation. |
| 2025-01-21 | JNJ | JOHNSON & JOHNSON SERVICES INC | NAVIGATORS GLOBAL LLC (FORMERLY DC NAVIGATORS, LLC) | $50K | General issues regarding health care and public health issues. Issues related to drug pricing, including the 340b program. Issues related to maternal health, patient access and treatment, health care science and technology. S.3679/H.R.7153 - Dr. Lorna Breen Health Care Provider Protection Reauthorization Act Issues related to cybersecurity for healthcare, including S.5218, the Health Infrastructure Security and Accountability Act of 2024. Issues related to the FY25 budget and appropriations process, including H.R. 10445, the Further Continuing Appropriations and Disaster Relief Supplemental Appropriations Act, 2025, and H.R.10545, the American Relief Act, 2025. |
| 2025-01-21 | JNJ | JOHNSON & JOHNSON SERVICES INC. | THE NICKLES GROUP, LLC | $40K | Issues related to mental health. Issues related to SUPPORT Act reauthorization. Monitored S. 2333, Pandemic and All-Hazards Preparedness and Response Act (PAHPA) reauthorization. Issues related to pharmacy benefit management, including alternative funding programs. Monitored issues related to healthcare workforce shortages. Monitored issues related to drug pricing. H.R. 10445, Furthering Continuing Appropriations and Disaster Relief Supplemental Appropriations Act, 2025, as it relates to pharmacy benefit management reforms and SUPPORT Act. H.R. 10545, The American Relief Act of 2025. Monitored implementation of P.L. 117-169, the Inflation Reduction Act, as it relates to drug pricing. Monitored issues related to Ambulatory Surgical Centers. H.R. 2666, the Medicaid VBPs for Patients (MVP) Act. Issues related to preventative services. Issues related to pharmacy benefit management. Issues related to the Medicaid Drug Rebate Program. Monitored issues related to Medicare physician payment. |